Citations (97)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Emidio Scarpellini, Lucrezia Laterza, Gianluca Ianiro, Jan Tack, Ludovico Abenavoli & Antonio Gasbarrini. (2016) Eluxadoline for the treatment of diarrhoea-predominant irritable bowel syndrome. Expert Opinion on Pharmacotherapy 17:10, pages 1395-1402.
Read now
Read now
Judy Nee, Mohammed Zakari & Anthony J Lembo. (2015) Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome. Expert Opinion on Pharmacotherapy 16:18, pages 2781-2792.
Read now
Read now
Shilan Mozaffari, Shekoufeh Nikfar & Mohammad Abdollahi. (2014) The safety of novel drugs used to treat irritable bowel syndrome. Expert Opinion on Drug Safety 13:5, pages 625-638.
Read now
Read now
Toshimi Chiba, Kazunari Yamamoto, Shoko Sato & Kazuyuki Suzuki. (2013) Long-term efficacy and safety of ramosetron in the treatment of diarrhea-predominant irritable bowel syndrome. Clinical and Experimental Gastroenterology 6, pages 123-128.
Read now
Read now
Michael Camilleri. (2013) Current and future pharmacological treatments for diarrhea-predominant irritable bowel syndrome. Expert Opinion on Pharmacotherapy 14:9, pages 1151-1160.
Read now
Read now
Shilan Mozaffari, Shekoufeh Nikfar & Mohammad Abdollahi. (2013) Metabolic and toxicological considerations for the latest drugs used to treat irritable bowel syndrome. Expert Opinion on Drug Metabolism & Toxicology 9:4, pages 403-421.
Read now
Read now
Ruben D Acosta & Brooks D Cash. (2011) Existing and emerging therapies for irritable bowel syndrome. Expert Opinion on Emerging Drugs 16:2, pages 389-402.
Read now
Read now
Ola Ghaith, Mustapha El-Halabi, Jana G Hashash & Ala I Sharara. (2010) Investigational agents for the irritable bowel syndrome. Expert Opinion on Investigational Drugs 19:10, pages 1161-1178.
Read now
Read now
Roland Andersson. (2008) Editorial. Scandinavian Journal of Gastroenterology 43:10, pages 1155-1157.
Read now
Read now
Articles from other publishers (88)
Kei Matsueda, Shin Fukudo, Masayuki Ogishima, Yuki Naito & Soichiro Nakamura. (2024) Efficacy and safety of peppermint oil for the treatment in Japanese patients with irritable bowel syndrome: a prospective, open-label, and single-arm study. BioPsychoSocial Medicine 18:1.
Crossref
Crossref
Wenjun Bai, Zhe Wang, Junwei Liang & Hualiang Deng. (2023) Atractylodes macrocephala-Paeonia lactiflora Class Formula for the Treatment of Irritable Bowel Syndrome: A Systematic Review With Meta-Analysis and Trial Sequential Analysis. Cureus.
Crossref
Crossref
Seung‐Bum Ryoo. (2023) Low anterior resection syndrome. Annals of Gastroenterological Surgery 7:5, pages 719-724.
Crossref
Crossref
Ankita Wal, Pranay Wal, Neha Verma, Awani Kumar Rai & Piyush Vatsha. (2023) Mechanism, Pathophysiology and Herbal Management-A Review on
Irritable Bowel Syndrome. The Natural Products Journal 13:3.
Crossref
Crossref
Xavier Alsina-Restoy, Rodrigo Torres-Castro, Estrella Caballería, Marina Sisó-Comabella, Bárbara Romano-Andrioni, Nancy Pérez-Rodas, Belén Noboa-Sevilla, Joel Francesqui, Fernanda Hernandez-Gonzalez & Jacobo Sellarés. (2023) Is Carob Flour Helpful in Reducing Diarrhoea Associated With Nintedanib?. Archivos de Bronconeumología 59:5, pages 341-343.
Crossref
Crossref
Toshihiko Tomita, Hirokazu Fukui, Daisuke Morishita, Sumire Mori, Tadayuki Oshima, Shinichiro Shinzaki & Hiroto Miwa. (2022) Efficacy of Serotonin Type 3 Receptor Antagonist Ramosetron on Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)-Like Symptoms in Patients with Quiescent Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Clinical Medicine 11:23, pages 6882.
Crossref
Crossref
Toru Arai & Yoshikazu Inoue. (2022) Two cases of nintedanib-induced diarrhoea treated using a 5-hydroxytryptamine type 3 receptor antagonist. ERJ Open Research 8:3, pages 00242-2022.
Crossref
Crossref
Kyung Ho Song. (2022) Antispasmodics. The Korean Journal of Helicobacter and Upper Gastrointestinal Research 22:2, pages 102-107.
Crossref
Crossref
Brigida Barberio, Edoardo V. Savarino, Christopher J. Black & Alexander C. Ford. (2021) Adverse events in trials of licensed drugs for irritable bowel syndrome with constipation or diarrhea: Systematic review and meta‐analysis. Neurogastroenterology & Motility 34:6.
Crossref
Crossref
Brigida Barberio, Edoardo Vincenzo Savarino, Christopher J. Black & Alexander C. Ford. (2022) Placebo Response Rates in Trials of Licensed Drugs for Irritable Bowel Syndrome With Constipation or Diarrhea: Meta-analysis. Clinical Gastroenterology and Hepatology 20:5, pages e923-e944.
Crossref
Crossref
Judy Nee & Anthony Lembo. (2021) Review Article: Current and future treatment approaches for IBS with diarrhoea (IBS‐D) and IBS mixed pattern (IBS‐M). Alimentary Pharmacology & Therapeutics 54:S1.
Crossref
Crossref
Muhammad Aziz, Jaya Kumar, Khairul Muhammad Nawawi, Raja Raja Ali & Norfilza Mokhtar. (2021) Irritable Bowel Syndrome, Depression, and Neurodegeneration: A Bidirectional Communication from Gut to Brain. Nutrients 13:9, pages 3061.
Crossref
Crossref
S -B Ryoo, J W Park, D W Lee, M A Lee, Y -H Kwon, M J Kim, S H Moon, S -Y Jeong & K J Park. (2021) Anterior resection syndrome: a randomized clinical trial of a 5-HT3 receptor antagonist (ramosetron) in male patients with rectal cancer. British Journal of Surgery 108:6, pages 644-651.
Crossref
Crossref
Michelle Bosman, Sigrid Elsenbruch, Maura Corsetti, Jan Tack, Magnus Simrén, Bjorn Winkens, Thimo Boumans, Ad Masclee & Daniel Keszthelyi. (2021) The placebo response rate in pharmacological trials in patients with irritable bowel syndrome: a systematic review and meta-analysis. The Lancet Gastroenterology & Hepatology 6:6, pages 459-473.
Crossref
Crossref
Shin Fukudo, Toshikatsu Okumura, Masahiko Inamori, Yusuke Okuyama, Motoyori Kanazawa, Takeshi Kamiya, Ken Sato, Akiko Shiotani, Yuji Naito, Yoshiko Fujikawa, Ryota Hokari, Tastuhiro Masaoka, Kazuma Fujimoto, Hiroshi Kaneko, Akira Torii, Kei Matsueda, Hiroto Miwa, Nobuyuki Enomoto, Tooru Shimosegawa & Kazuhiko Koike. (2021) Evidence-based clinical practice guidelines for irritable bowel syndrome 2020. Journal of Gastroenterology 56:3, pages 193-217.
Crossref
Crossref
Esther Colomier, Joost Algera & Chloé Melchior. (2021) Pharmacological Therapies and Their Clinical Targets in Irritable Bowel Syndrome With Diarrhea. Frontiers in Pharmacology 11.
Crossref
Crossref
Radomir Juza, Premysl Vlcek, Eva Mezeiova, Kamil Musilek, Ondrej Soukup & Jan Korabecny. (2020)
Recent advances with 5‐HT
3
modulators for neuropsychiatric and gastrointestinal disorders
. Medicinal Research Reviews 40:5, pages 1593-1678.
Crossref
Crossref
Azadeh Seddighnia, Borna Tadayon Najafabadi, Kiandokht Ghamari, Ahmad Ali Noorbala, Naser Ebrahimi Daryani, Ladan Kashani & Shahin Akhondzadeh. (2019) Vortioxetine effects on quality of life of irritable bowel syndrome patients: A randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Pharmacy and Therapeutics 45:1, pages 97-104.
Crossref
Crossref
Christopher J Black, Nicholas E Burr, Michael Camilleri, David L Earnest, Eamonn MM Quigley, Paul Moayyedi, Lesley A Houghton & Alexander C Ford. (2020) Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis. Gut 69:1, pages 74-82.
Crossref
Crossref
Anna Zielińska. 2020. A Comprehensive Overview of Irritable Bowel Syndrome. A Comprehensive Overview of Irritable Bowel Syndrome
145
166
.
Yoshiyuki Kimura. (2019) Effects of kampo medicine keishikashakuyakuto on large intestine disease in mice. Traditional & Kampo Medicine 6:3, pages 165-172.
Crossref
Crossref
Jieun Shin, Kwang Joon Kim & Joon Seok Bang. (2019) A Study of Irritable Bowel Syndrome and Stress on Female College Students in Korea. Korean Journal of Clinical Pharmacy 29:3, pages 156-165.
Crossref
Crossref
Kok Ann Gwee, Sutep Gonlachanvit, Uday C Ghoshal, Andrew S B Chua, Hiroto Miwa, Justin Wu, Young-Tae Bak, Oh Young Lee, Ching-Liang Lu, Hyojin Park, Minhu Chen, Ari F Syam, Philip Abraham, Jose Sollano, Chi-Sen Chang, Hidekazu Suzuki, Xiucai Fang, Shin Fukudo, Myung-Gyu Choi, Xiaohua Hou & Michio Hongo. (2019) Second Asian Consensus on Irritable Bowel Syndrome. Journal of Neurogastroenterology and Motility 25:3, pages 343-362.
Crossref
Crossref
Alexander C. Ford. 2019. Evidence‐based Gastroenterology and Hepatology 4e. Evidence‐based Gastroenterology and Hepatology 4e
306
331
.
Alessandro Adriani, Davide G. Ribaldone, Marco Astegiano, Marilena Durazzo, Giorgio M. Saracco & Rinaldo Pellicano. (2018) Irritable bowel syndrome: the clinical approach. Panminerva Medica 60:4.
Crossref
Crossref
Qingqing Qi, Yan Zhang, Feixue Chen, Xiuli Zuo & Yanqing Li. (2018) Ramosetron for the treatment of irritable bowel syndrome with diarrhea: a systematic review and meta-analysis of randomized controlled trials. BMC Gastroenterology 18:1.
Crossref
Crossref
Fermín Mearin, Enrique Rey & Cecilio Santander. (2018) Síndrome del intestino irritable: cómo mejorar la toma de decisiones en la práctica clínica. Medicina Clínica 151:12, pages 489-497.
Crossref
Crossref
Fermín Mearin, Enrique Rey & Cecilio Santander. (2018) Irritable bowel syndrome: How to improve decision making in clinical practice. Medicina Clínica (English Edition) 151:12, pages 489-497.
Crossref
Crossref
Michael Camilleri. (2018) Management Options for Irritable Bowel Syndrome. Mayo Clinic Proceedings 93:12, pages 1858-1872.
Crossref
Crossref
Lingping Zhu, Yunhui Ma, Shasha Ye & Zhiqun Shu. (2018) Acupuncture for Diarrhoea-Predominant Irritable Bowel Syndrome: A Network Meta-Analysis. Evidence-Based Complementary and Alternative Medicine 2018, pages 1-12.
Crossref
Crossref
Kyung Ho Song, Hye-Kyung Jung, Hyun Jin Kim, Hoon Sup Koo, Yong Hwan Kwon, Hyun Duk Shin, Hyun Chul Lim, Jeong Eun Shin, Sung Eun Kim, Dae Hyeon Cho, Jeong Hwan Kim & Hyun Jung Kim. (2018) Clinical Practice Guidelines for Irritable Bowel Syndrome in Korea, 2017 Revised Edition. Journal of Neurogastroenterology and Motility 24:2, pages 197-215.
Crossref
Crossref
Orla Craig. (2018) New therapies in Irritable Bowel Syndrome. Current Opinion in Gastroenterology 34:1, pages 50-56.
Crossref
Crossref
Motoko Ida, Akito Nishida, Hiraku Akiho, Yoshihiro Nakashima, Kei Matsueda & Shin Fukudo. (2017) Randomized, placebo-controlled, phase IV pilot study of ramosetron to evaluate the co-primary end points in male patients with irritable bowel syndrome with diarrhea. BioPsychoSocial Medicine 11:1.
Crossref
Crossref
Motoko Ida, Akito Nishida, Hiraku Akiho, Yoshihiro Nakashima, Kei Matsueda & Shin Fukudo. (2017) Evaluation of the irritable bowel syndrome severity index in Japanese male patients with irritable bowel syndrome with diarrhea. BioPsychoSocial Medicine 11:1.
Crossref
Crossref
Michael Camilleri & Alexander Ford. (2017) Pharmacotherapy for Irritable Bowel Syndrome. Journal of Clinical Medicine 6:11, pages 101.
Crossref
Crossref
S. Fukudo, K. Matsueda, K. Haruma, M. Ida, H. Hayase, H. Akiho, Y. Nakashima & M. Hongo. (2017) Optimal dose of ramosetron in female patients with irritable bowel syndrome with diarrhea: A randomized, placebo‐controlled phase II study. Neurogastroenterology & Motility 29:6.
Crossref
Crossref
Yongping Zheng, Ting Yu, Yurong Tang, Wenjie Xiong, Xiaoxue Shen, Ling Jiang & Lin Lin. (2017) Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials. PLOS ONE 12:3, pages e0172846.
Crossref
Crossref
Ryo Katsumata, Akiko Shiotani, Takahisa Murao, Manabu Ishii, Minoru Fujita, Hiroshi Matsumoto & Ken Haruma. (2017) Gender Differences in Serotonin Signaling in Patients with Diarrhea-predominant Irritable Bowel Syndrome. Internal Medicine 56:9, pages 993-999.
Crossref
Crossref
Maciej Sałaga & Paula Mosińska. 2017. Introduction to Gastrointestinal Diseases Vol. 1. Introduction to Gastrointestinal Diseases Vol. 1
43
61
.
Jasmeet S. Mokha & Jeffrey S. Hyams. 2017. Pediatric Neurogastroenterology. Pediatric Neurogastroenterology
399
410
.
Shin Fukudo, Yoshikazu Kinoshita, Toshikatsu Okumura, Motoko Ida, Kenta Hayashi, Hiraku Akiho, Yoshihiro Nakashima & Ken Haruma. (2016) Effect of ramosetron in female patients with irritable bowel syndrome with diarrhea: a phase III long-term study. Journal of Gastroenterology 51:9, pages 874-882.
Crossref
Crossref
Amy E. Foxx-Orenstein. (2016) New and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologists. Therapeutic Advances in Gastroenterology 9:3, pages 354-375.
Crossref
Crossref
Brian E. Lacy, Fermín Mearin, Lin Chang, William D. Chey, Anthony J. Lembo, Magnus Simren & Robin Spiller. (2016) Bowel Disorders. Gastroenterology 150:6, pages 1393-1407.e5.
Crossref
Crossref
Michael Camilleri, Lionel Buéno, Viola Andresen, Fabrizio De Ponti, Myung-Gyu Choi & Anthony Lembo. (2016) Pharmacologic, Pharmacokinetic, and Pharmacogenomic Aspects of Functional Gastrointestinal Disorders. Gastroenterology 150:6, pages 1319-1331.e20.
Crossref
Crossref
Shin Fukudo, Yoshikazu Kinoshita, Toshikatsu Okumura, Motoko Ida, Hiraku Akiho, Yoshihiro Nakashima, Akito Nishida & Ken Haruma. (2016) Ramosetron Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women. Gastroenterology 150:2, pages 358-366.e8.
Crossref
Crossref
Robin Spiller. (2016) Irritable bowel syndrome: new insights into symptom mechanisms and advances in treatment. F1000Research 5, pages 780.
Crossref
Crossref
Michael Camilleri & Alexander C. Ford. 2017. Gastrointestinal Pharmacology. Gastrointestinal Pharmacology
75
113
.
Kazunari Tominaga, Yoshiko Fujikawa, Fumio Tanaka, Tetsuya Tanigawa, Toshio Watanabe, Yasuhiro Fujiwara & Tetsuo Arakawa. (2015) Pharmacological Treatment for Functional Dyspepsia and Irritable Bowel Syndrome : Current Standards and Promising Therapies. Journal of General and Family Medicine 16:4, pages 242-251.
Crossref
Crossref
Yang Won Min & Poong-Lyul Rhee. (2015) The clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D). Therapeutic Advances in Gastroenterology 8:3, pages 136-142.
Crossref
Crossref
A. Shiotani, H. Kusunoki, M. Ishii, H. Imamura, N. Manabe, T. Kamada, J. Hata, J. L. Merchant & K. Haruma. (2014)
Pilot study of Biomarkers for predicting effectiveness of ramosetron in diarrhea‐predominant irritable bowel syndrome: expression of
S100A10
and polymorphisms of
TPH
1
. Neurogastroenterology & Motility 27:1, pages 82-91.
Crossref
Crossref
Shin Fukudo, Hiroshi Kaneko, Hirotada Akiho, Masahiko Inamori, Yuka Endo, Toshikatsu Okumura, Motoyori Kanazawa, Takeshi Kamiya, Ken Sato, Toshimi Chiba, Kenji Furuta, Shigeru Yamato, Tetsuo Arakawa, Yoshihide Fujiyama, Takeshi Azuma, Kazuma Fujimoto, Tetsuya Mine, Soichiro Miura, Yoshikazu Kinoshita, Kentaro Sugano & Tooru Shimosegawa. (2014) Evidence-based clinical practice guidelines for irritable bowel syndrome. Journal of Gastroenterology 50:1, pages 11-30.
Crossref
Crossref
Klara Garsed, Julia Chernova, Margaret Hastings, Ching Lam, Luca Marciani, Gulzar Singh, Amanda Henry, Ian Hall, Peter Whorwell & Robin Spiller. (2014) A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut 63:10, pages 1617-1625.
Crossref
Crossref
Jose L. Barboza, Nicholas J. Talley & Baharak Moshiree. (2014) Current and Emerging Pharmacotherapeutic Options for Irritable Bowel Syndrome. Drugs 74:16, pages 1849-1870.
Crossref
Crossref
Alexander C Ford, Paul Moayyedi, Brian E Lacy, Anthony J Lembo, Yuri A Saito, Lawrence R Schiller, Edy E Soffer, Brennan M R Spiegel & Eamonn M M Quigley. (2014) American College of Gastroenterology Monograph on the Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation. American Journal of Gastroenterology 109, pages S2-S26.
Crossref
Crossref
Tim Vanuytsel, Jan F. Tack & Guy E. Boeckxstaens. (2014) Treatment of abdominal pain in irritable bowel syndrome. Journal of Gastroenterology 49:8, pages 1193-1205.
Crossref
Crossref
Shin Fukudo, Motoko Ida, Hiraku Akiho, Yoshihiro Nakashima & Kei Matsueda. (2014) Effect of Ramosetron on Stool Consistency in Male Patients With Irritable Bowel Syndrome With Diarrhea. Clinical Gastroenterology and Hepatology 12:6, pages 953-959.e4.
Crossref
Crossref
David D. Manning, Cheng Guo, Zhenjun Zhang, Kristen N. Ryan, Jennifer Naginskaya, Sok Hui Choo, Liaqat Masih, William G. Earley, Jonathan D. Wierschke, Amy S. Newman, Catherine A. Brady, Nicholas M. Barnes & Peter R. Guzzo. (2014) The discovery of diazepinone-based 5-HT3 receptor partial agonists. Bioorganic & Medicinal Chemistry Letters 24:11, pages 2578-2581.
Crossref
Crossref
Mari Nakata-Fukuda, Takuya Hirata, Yoshihiro Keto, Mayumi Yamano, Toshihide Yokoyama & Yasuo Uchiyama. (2014) Inhibitory effect of the selective serotonin 5-HT3 receptor antagonist ramosetron on duodenal acidification-induced gastric hypersensitivity in rats. European Journal of Pharmacology 731, pages 88-92.
Crossref
Crossref
Shin Fukudo. (2013) Stress and visceral pain: Focusing on irritable bowel syndrome. Pain 154:Supplement 1, pages S63-S70.
Crossref
Crossref
Michael Camilleri. (2013) Pharmacological agents currently in clinical trials for disorders in neurogastroenterology. Journal of Clinical Investigation 123:10, pages 4111-4120.
Crossref
Crossref
Yoo Mi Park, Young Ju Lee, Young Ho Lee, Tae Il Kim & Hyojin Park. (2013) Effects of Ramosetron on Gastrointestinal Transit of Guinea Pig. Journal of Neurogastroenterology and Motility 19:1, pages 36-41.
Crossref
Crossref
Nicholas A. Moore, Bruce J. Sargent, David D. Manning & Peter R. Guzzo. (2012)
Partial Agonism of 5-HT
3
Receptors: A Novel Approach to the Symptomatic Treatment of IBS-D
. ACS Chemical Neuroscience 4:1, pages 43-47.
Crossref
Crossref
Magnus Halland & Nicholas J. Talley. (2012) New treatments for IBS. Nature Reviews Gastroenterology & Hepatology 10:1, pages 13-23.
Crossref
Crossref
Takuya Hirata, Yoshihiro Keto, Mayumi Yamano, Toshihide Yokoyama, Takanori Sengoku & Nobuo Seki. (2012) Inhibitory effect of ramosetron on corticotropin releasing factor‐ and soybean oil‐induced delays in gastric emptying in rats. Journal of Gastroenterology and Hepatology 27:9, pages 1505-1511.
Crossref
Crossref
Yasushi Fukushima, Hidekazu Suzuki, Juntaro Matsuzaki, Arihiro Kiyosue & Toshifumi Hibi. (2012) Efficacy of Solifenacin on Irritable Bowel Syndrome With Diarrhea: Open-label Prospective Pilot Trial. Journal of Neurogastroenterology and Motility 18:3, pages 317-323.
Crossref
Crossref
Robin Spiller & Ching Lam. (2012) An Update on Post-infectious Irritable Bowel Syndrome: Role of Genetics, Immune Activation, Serotonin and Altered Microbiome. Journal of Neurogastroenterology and Motility 18:3, pages 258-268.
Crossref
Crossref
Bong Ki Cha, Chang Hwan Choi & Sae Kyung Chang. (2012) Efficacy of Ramosetron in Male Patients With Irritable Bowel Syndrome With Diarrhea (Neurogastroenterol Motil 2011;23:1098-1104). Journal of Neurogastroenterology and Motility 18:2, pages 224-226.
Crossref
Crossref
Robin Spiller. 2012. Textbook of Clinical Gastroenterology and Hepatology. Textbook of Clinical Gastroenterology and Hepatology
472
481
.
Michael Camilleri & Carlo Di Lorenzo. (2012) Brain‐Gut Axis. Journal of Pediatric Gastroenterology and Nutrition 54:4, pages 446-453.
Crossref
Crossref
M Camilleri. (2011) Pharmacology of the New Treatments for Lower Gastrointestinal Motility Disorders and Irritable Bowel Syndrome. Clinical Pharmacology & Therapeutics 91:1, pages 44-59.
Crossref
Crossref
K. J. Lee, N. Y. Kim, J. K. Kwon, K. C. Huh, O. Y. Lee, J. S. Lee, S. C. Choi, C. I. Sohn, S. J. Myung, H. J. Park, M. K. Choi, Y. T. Bak & P. L. Rhee. (2011) Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine. Neurogastroenterology & Motility 23:12, pages 1098-1104.
Crossref
Crossref
T. Mizushima. (2011) Drug discovery and development focusing on existing medicines: drug re-profiling strategy. Journal of Biochemistry 149:5, pages 499-505.
Crossref
Crossref
Motoyori Kanazawa, Michio Hongo & Shin Fukudo. (2011) Visceral hypersensitivity in irritable bowel syndrome. Journal of Gastroenterology and Hepatology 26:s3, pages 119-121.
Crossref
Crossref
Soichiro Miura, Kentaro Sugano, Yoshikazu Kinoshita, Kwong Ming Fock, Khean Lee Goh & Peter Gibson. (2011) Diagnosis and treatment of functional gastrointestinal disorders in the Asia‐Pacific region: A survey of current practices. Journal of Gastroenterology and Hepatology 26:s3, pages 2-11.
Crossref
Crossref
Orla F. Craig & Eamonn M. M. Quigley. (2010) Current and emerging therapies for the management of functional gastrointestinal disorders. Therapeutic Advances in Chronic Disease 2:2, pages 87-99.
Crossref
Crossref
Anita Sainsbury & Alexander C. Ford. (2010) Treatment of irritable bowel syndrome: beyond fiber and antispasmodic agents. Therapeutic Advances in Gastroenterology 4:2, pages 115-127.
Crossref
Crossref
M. Camilleri. (2011) LX-1031, a tryptophan 5-hydroxylase inhibitor, and its potential in chronic diarrhea associated with increased serotonin. Neurogastroenterology & Motility 23:3, pages 193-200.
Crossref
Crossref
Robin C Spiller. (2011) Targeting the 5-HT3 receptor in the treatment of irritable bowel syndrome. Current Opinion in Pharmacology 11:1, pages 68-74.
Crossref
Crossref
Joong Goo KwonKyung Sik ParkJung Ho ParkJae Myung ParkCheol Hee ParkKwang Jae LeeHyo-Jin ParkJong Chul Rhee. (2011) Guidelines for the Treatment of Irritable Bowel Syndrome. The Korean Journal of Gastroenterology 57:2, pages 82.
Crossref
Crossref
David D. Manning, Christopher L. Cioffi, Alexander Usyatinsky, Kevin Fitzpatrick, Liaqat Masih, Cheng Guo, Zhenjun Zhang, Sok Hui Choo, M. Inthikhab Sikkander, Kristen N. Ryan, Jennifer Naginskaya, Carla Hassler, Svetlana Dobritsa, Jonathan D. Wierschke, William G. Earley, Amy S. Butler, Catherine A. Brady, Nicholas M. Barnes, Marlene L. Cohen & Peter R. Guzzo. (2011) Novel serotonin type 3 receptor partial agonists for the potential treatment of irritable bowel syndrome. Bioorganic & Medicinal Chemistry Letters 21:1, pages 58-61.
Crossref
Crossref
Zhicai Yang, David J. Fairfax, Jun-Ho Maeng, Liaqat Masih, Alexander Usyatinsky, Carla Hassler, Soshanna Isaacson, Kevin Fitzpatrick, Russell J. DeOrazio, Jianqing Chen, James P. Harding, Matthew Isherwood, Svetlana Dobritsa, Kevin L. Christensen, Jonathan D. Wierschke, Brian I. Bliss, Lisa H. Peterson, Cathy M. Beer, Christopher Cioffi, Michael Lynch, W. Martin Rennells, Justin J. Richards, Timothy Rust, Yuri L. Khmelnitsky, Marlene L. Cohen & David D. Manning. (2010) Discovery of 2-substituted benzoxazole carboxamides as 5-HT3 receptor antagonists. Bioorganic & Medicinal Chemistry Letters 20:22, pages 6538-6541.
Crossref
Crossref
Noriaki Manabe, Archana S. Rao, Banny S. Wong & Michael Camilleri. (2010) Emerging Pharmacologic Therapies for Irritable Bowel Syndrome. Current Gastroenterology Reports 12:5, pages 408-416.
Crossref
Crossref
A. C. Ford & P. Moayyedi. (2010) Meta‐analysis: factors affecting placebo response rate in the irritable bowel syndrome. Alimentary Pharmacology & Therapeutics 32:2, pages 144-158.
Crossref
Crossref
Shin Fukudo. (2010) 3) Irritable Bowel Syndrome (IBS)3）過敏性腸症候群（IBS）. Nihon Naika Gakkai Zasshi 99:9, pages 2146-2157.
Crossref
Crossref
M. CAMILLERI. (2009) Review article: new receptor targets for medical therapy in irritable bowel syndrome. Alimentary Pharmacology & Therapeutics 31:1, pages 35-46.
Crossref
Crossref
Richárd Róka, Krisztina Gecse & Tibor Wittmann. (2009) Novel strategies and future landmarks in the treatment of irritable bowel syndrome. Therapy 6:4, pages 603-613.
Crossref
Crossref
Full-Young Chang & Ching-Liang Lu. (2009) Treatment of Irritable Bowel Syndrome Using Complementary and Alternative Medicine. Journal of the Chinese Medical Association 72:6, pages 294-300.
Crossref
Crossref
Takuya Hirata, Toshiyuki Funatsu, Yoshihiro Keto, Shinobu Akuzawa, Hiraku Akiho, Akito Nishida, Masao Sasamata & Keiji Miyata. (2009) Pharmacological and clinical profile of ramosetron hydrochloride (Irribow®), a novel therapeutic agent for irritable bowel syndrome with diarrhea. Folia Pharmacologica Japonica 133:5, pages 281-291.
Crossref
Crossref